Laurion Capital Management LP
Source: SEC Form 13F · as of Mar 2026Laurion Capital Management LP holds 23 biotech & pharma companies tracked by BioSniper, totaling $253.3M in value as of Mar 2026 (SEC Form 13F).
Companies held
23
Total value held
$253.3M
BioSniper AIPage evidence connected
Prepared research question
What matters most for BridgeBio Pharma, Inc. (BBIO)—catalysts, financial risk and supporting evidence?
Run cited research
Traceable citations · Unknowns marked
| Company | Shares | Value |
|---|---|---|
| BBIOBridgeBio Pharma, Inc. | 1,262,651 | $93.8M |
| MLYSMineralys Therapeutics, Inc. | 2,232,040 | $60.5M |
| NUVBNuvation Bio Inc. | 7,822,638 | $33.6M |
| BBOTBridgeBio Oncology Therapeutics, Inc. | 1,922,656 | $17.2M |
| PYXSPyxis Oncology, Inc. | 4,997,333 | $7.3M |
| VORVor Biopharma Inc. | 318,670 | $5.7M |
| PEPGPepGen Inc. | 2,750,855 | $4.9M |
| AUTLAutolus Therapeutics plc | 3,316,626 | $4.6M |
| CRDFCardiff Oncology, Inc. | 2,646,738 | $4.3M |
| AARDAardvark Therapeutics, Inc. | 1,034,459 | $3.9M |
| RLYBRallybio Corp | 302,756 | $2.7M |
| GILDGILEAD SCIENCES, INC. | 17,812 | $2.5M |
| BMYBRISTOL MYERS SQUIBB CO | 36,100 | $2.2M |
| AZNASTRAZENECA PLC | 9,500 | $1.9M |
| ABBVAbbVie Inc. | 8,395 | $1.8M |
| AKTSAktis Oncology Inc. | 100,000 | $1.8M |
| ALNYALNYLAM PHARMACEUTICALS, INC. | 4,431 | $1.5M |
| ABOSAcumen Pharmaceuticals, Inc. | 525,444 | $1.2M |
| PMPhilip Morris International Inc | 4,849 | $802K |
| AGMBAgomAb Therapeutics NV | 50,000 | $525K |
| PLRXPLIANT THERAPEUTICS, INC. | 412,796 | $520K |
| CRBPCorbus Pharmaceuticals Holdings, Inc. | 19,600 | $184K |
| MYGNMYRIAD GENETICS INC | 14,443 | $65K |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.